A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

Daisuke Sakai, Toshihiko Doi, Volker Wacheck et al.|Cancer Chemotherapy and Pharmacology|2017

Cited by 31